Drug Trial Radar · NCT07256392
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
1,370
Planned (sponsor's estimate)
Start
Nov 25, 2025
Primary completion
Sep 2028
Study completion Sep 2028
Sponsor
- Lead sponsor
- Celldex TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this extension study is to collect long-term efficacy and safety data on barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who completed the treatment and follow-up periods of the Phase 3 clinical trials. This study will also fulfill the Celldex commitment to provide post-trial access to participants who have completed the phase 3 studies, where applicable.
Conditions
- Chronic Spontaneous Urticaria
Interventions
barzolvolimabBiological
Subcutaneous Administration
Standard of CareOther
Observational/Standard of Care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to disease worsening or treatment failure through Week 52 based on the occurrence of UAS7 (Urticaria Activity Score) of 16 or greater.Time frame: From Day 1 (baseline) to Week 52.
- Time to disease worsening or treatment failure through Week 52 based on the occurrence of the discontinuation of barzolvolimab in Group 2 due to lack of efficacy or to a treatment related adverse event.Time frame: From Day 1 (baseline) to Week 52.
- Time to disease worsening or treatment failure through Week 52 based on the occurrence of first use of strongly confounding prohibited medication (Group 1 or 2) or use of barzolvolimab in Group 1.Time frame: From Day 1 (baseline) to Week 52.
Locations
201 sites in 30 countries. Site status is shown where the registry gives one.
Cahaba Dermatology & Skin Health Center, LLC
Birmingham, Alabama
Medical Research of Arizona
Scottsdale, Arizona
Center for Dermatology & Plastic Surgery - Avacare
Scottsdale, Arizona
Kern Research
Bakersfield, California
Allergy and Asthma Associates of Southern California - Laguna Niguel - CRN
Laguna Niguel, California
Dermatology Research Associates
Los Angeles, California
LA Universal Research Center, Inc.
Los Angeles, California
Asthma and Allergy Associates
Colorado Springs, Colorado
Encore Medical Research of Boynton Beach LLC
Boynton Beach, Florida
Dolphin Medical Research
Doral, Florida
Direct Helpers Research Center
Hialeah, Florida
GSI Clinical Research
Margate, Florida
Miami Dade Medical Research Institute, LLC
Miami, Florida
Deluxe Health Center
Miami Lakes, Florida
Sarasota Clinical Research
Sarasota, Florida
GCP, Global Clinical Professionals
St. Petersburg, Florida
Advanced Clinical Research Institute (ACRI) - Florida
Tampa, Florida
Centricity Research Columbus Dermatology
Columbus, Georgia
Endeavor Health
Skokie, Illinois
The South Bend Clinic - Avacare
South Bend, Indiana
Allergy and Asthma Specialists PSC
Owensboro, Kentucky
John Hopkins University
Baltimore, Maryland
DermAssociates, LLC
Rockville, Maryland
Institute for Asthma and Allergy
Wheaton, Maryland
Michigan Center for Research Co., LLC
Clarkston, Michigan
Respiratory Medicine Research Institute of Michigan PLC
Ypsilanti, Michigan
The Derm Institute of West Michigan
Caledonia, Missouri
Midwest Clinical Research
St Louis, Missouri
Washington University School of Medicine
St Louis, Missouri
Montana Medical Research, Inc.
Missoula, Montana
Skin Specialists, PC dba Schlessinger MD
Omaha, Nebraska
Allergy Partners of NJ, PC
Ocean City, New Jersey
Markowitz Medical PLLC dba OptiSkin Medical
New York, New York
Bexley Dermatology Research
Bexley, Ohio
Auni Allergy
Findlay, Ohio
Toledo Institute for Clinical Research
Toledo, Ohio
Portland Allergy and Asthma
Clackamas, Oregon
Clinical Partners LLC
Johnston, Rhode Island
Alina Clinical Trials LLC
Dallas, Texas
Western Sky Medical Research
El Paso, Texas
Showing 40 of 201 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.